Colon cancer risks down, and more

October 11, 2008

Risk of Colon Cancer Associated with Genetic Variants.

Researchers from several medical centers have reported that genetic changes in

the surrounding region of the ADIPQ gene are associated with a decrease in the

risk of developing colorectal cancer. Results such as these may aid in the

understanding of genetic risk of various cancers, ultimately changing the way in

which cancer is managed. These results were recently published in the October 1,

2008 issue of the Journal of the American Medical Association.

When do cancer patients need help?

a.. When you have no insurance or have lost your insurance through a job change.

If you have no coverage for the particular drug you are on or have no drug

coverage at all, you should apply for assistance. Most of the drug companies

have programs for their drug, particularly if it is a " brand name " drug. Use our

Drug Assistance Programs to get the application and particulars for the drug or

drugs that you are on.

a.. When you have no coverage for your particular drug. You may have coverage

when your drug is given in the doctor's office or hospital, but you have no

prescription coverage. Or, you may have coverage for all drugs, but there is no

coverage for your drug with your diagnosis. In both of these cases, you should

apply for assistance. Click on the Drug Assistance Programs.

a.. More complete information can be found here:

a..

r-treatment-costs.htm

How I treat chronic myeloid leukemia in the imatinib era, by: M. Goldman,

Department of Haematology, Imperial College at Hammersmith Hospital, London,

United Kingdom

Although it is now generally accepted that imatinib is the best initial

treatment for patients newly diagnosed with chronic myeloid leukemia (CML) in

chronic phase, a number of questions remain unanswered. For example, (1) Is

imatinib the best initial treatment for every chronic-phase patient? (2) At what

dose should imatinib be started? (3) How should response to treatment be

monitored? (4) For how long should the drug be continued in patients who have

achieved and maintain a complete molecular response? (5) How does one handle a

patient who achieves a 2-log but not a 3-log reduction in BCR-ABL transcripts?

For the rest of the abstract in BLOOD, click here:

Have a good read,

Lottie

Recommended Posts